[HTML][HTML] Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6–16 years
P Veggiotti, S Józwiak, F Kirkham, J Moreira… - Epilepsy & Behavior, 2022 - Elsevier
Abstract Objective In Europe, eslicarbazepine acetate (ESL) is approved as adjunctive
therapy for the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is …
therapy for the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is …
[PDF][PDF] Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6–16 years
P Veggiotti, S Józwiak, F Kirkham, J Moreira… - Epilepsy & …, 2022 - scholar.archive.org
abstract Objective: In Europe, eslicarbazepine acetate (ESL) is approved as adjunctive
therapy for the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is …
therapy for the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is …
Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6-16 years
P Veggiotti, S Józwiak, F Kirkham… - … & behavior: E&B, 2022 - pubmed.ncbi.nlm.nih.gov
Objective In Europe, eslicarbazepine acetate (ESL) is approved as adjunctive therapy for the
treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is approved as …
treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is approved as …
Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6-16 years
P Veggiotti, S Józwiak, F Kirkham, J Moreira… - Epilepsy & …, 2022 - discovery.ucl.ac.uk
OBJECTIVE: In Europe, eslicarbazepine acetate (ESL) is approved as adjunctive therapy for
the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is approved as …
the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is approved as …
Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6-16 years
P Veggiotti, S Jozwiak, F Kirkham, J Moreira… - Epilepsy & …, 2022 - eprints.soton.ac.uk
Objective: In Europe, eslicarbazepine acetate (ESL) is approved as adjunctive therapy for
the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is approved as …
the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is approved as …
Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6–16 years
P Veggiotti, S Jozwiak, F Kirkham, J Moreira… - EPILEPSY & …, 2022 - air.unimi.it
Objective: In Europe, eslicarbazepine acetate (ESL) is approved as adjunctive therapy for
the treatment of focal seizures (FS) in children aged > 6 years. In the US, ESL is approved …
the treatment of focal seizures (FS) in children aged > 6 years. In the US, ESL is approved …
[PDF][PDF] Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6–16 years
P Veggiotti, S Józwiak, F Kirkham, J Moreira… - Epilepsy & …, 2022 - academia.edu
abstract Objective: In Europe, eslicarbazepine acetate (ESL) is approved as adjunctive
therapy for the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is …
therapy for the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is …
[HTML][HTML] Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6–16 years
P Veggiotti, S Józwiak, F Kirkham… - Epilepsy & …, 2022 - epilepsybehavior.com
Abstract Objective In Europe, eslicarbazepine acetate (ESL) is approved as adjunctive
therapy for the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is …
therapy for the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is …
Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6-16 years.
P Veggiotti, S Józwiak, F Kirkham, J Moreira… - Epilepsy & Behavior …, 2022 - europepmc.org
Objective In Europe, eslicarbazepine acetate (ESL) is approved as adjunctive therapy for the
treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is approved as …
treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is approved as …